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Abstract
RAS proteins are key signalling hubs that are oncogenically mutated in 30% of all cancer cases. Three
genes encode almost identical isoforms that are ubiquitously expressed, but are not functionally redundant.
The network responses associated with each isoform and individual oncogenic mutations remain to be
fully characterized. In the present article, we review recent data deﬁning the differences between the RAS
isoforms and their most commonly mutated codons and discuss the underlying mechanisms.
Introduction
RAS proteins are membrane-bound small GTPases that act
as molecular switches downstream of cell-surface receptors.
Upon GTP binding, RAS changes conformation, revealing
an effector-binding site that can interact with proteins
harbouring a RAS-binding domain [1]. Relocalization of
effectors to the membrane promotes interactions with their
regulators, substrates and other effectors inducing a signalling
response. These include activation of the RAF/MAPK
(mitogen-activated protein kinase) pathway that promotes
cell proliferation and the PI3K (phosphoinositide 3-
kinase)/Akt pathway that promotes cell survival [2].
In the human genome, three genes encode HRAS, KRAS
and NRAS. Alternative splicing of HRAS and KRAS
generates protein variants with altered C-termini [3]. The N-
terminal half of the RAS isoforms share complete amino acid
identity; this includes the effector binding domain and the
majority of residues responsible for co-ordinatingGDP/GTP
binding, GTPase activity and regulators of RAS activity.
The major area of protein sequence divergence between the
isoforms is found in the final 26 amino acids. This region
is post-translationally modified to enable membrane binding
and correct localization of each of the RAS isoforms [4].
Despite their similarity, RAS proteins are not functionally
redundant. Furthermore, the oncogenic mutations that make
RAS constitutively active may not all be equivalent in their
functional consequences. We discuss the evidence for this
together with the potential mechanisms underlying these
phenomena.
Oncogenic RAS
RAS proteins cycle between the inactive GDP-bound and
the active GTP-bound conformations (Figure 1). This
cycle is controlled by regulatory GEFs (guanine-nucleotide-
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exchange factors) andGAPs (GTPase-activatingproteins) [5].
Mutations of RAS at codons 12, 13 or 61 render the protein
insensitive to GAP function and/or impair GTPase activity,
resulting in a constitutively active protein that promotes
oncogenesis [6]. Importantly, all three RAS isoforms share
complete sequence identity at these sites and the mutations
are assumed to have equivalent effects on the activity of
each isoform [4]. Despite this, KRAS is the most frequently
mutated isoform and mutation of each RAS protein exhibits
coupling with a specific subset of cancers [7,8]. For example,
KRAS is strongly associated with pancreatic, colorectal and
lung cancers, whereas NRAS is the isoform most frequently
mutated in haemopoietic tumours. HRAS mutations are
rarely detected in tumours.
The reason for the bias in RAS mutations associated
with individual cancers is unclear, although several models
have been proposed. One simple possibility is that isoform-
specificity could mean that a more oncogenic network
response is generated when KRAS is rendered constitutively
active by mutation compared with the other RAS isoforms.
This is supported by mouse models harbouring G12D
mutatedKRAS that exhibitedwidespread colonic hyperplasia
and neoplasia. In contrast, NRAS G12D stimulated cell
survival pathways [9]. Further support for the oncogenic
potency of the KRAS signalling network comes from
comparative studies utilizing ectopic expression of G12V
mutated RAS isoforms. This revealed that KRAS promotes
endodermal stem cell expansion, whereas NRAS and HRAS
do not [6,10]. This is significant because many cancers of
endodermal origin such as pancreatic, lung and colorectal
cancer are strongly associated with KRAS mutations. This
suggests amodelwhere theKRAS coupling to specific cancers
is due to its role in expanding cancer progenitor cells in these
tissues.
Recently, an alternative model for KRAS mutation
predominance in cancer was suggested on the basis of the
likely relative protein expression levels of each isoform.
Analysis of the DNA sequence of KRAS revealed a strong
bias for rare codon usage resulting in significantly reduced
protein translation compared with a codon-optimized KRAS
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Figure 1 RAS activation and signalling
RAS cycling between the inactive GDP-bound and the active
GTP-bound conformations is controlled by GEFs and GAPs. GTP-bound
RAS can interact with more than 20 effectors that control many
cellular functions. AF6, ALL-1-fusion partner in chromosome 6; ERK,
extracellular-signal-regulated kinase; MEK, MAPK/ERK kinase; RASSF,
RAS-association domain family.
Figure 2 Relative RAS isoform protein abundance in a panel of
cancer cell lines
KRAS is the most abundant isoform in the majority of cell lines, whereas
HRAS typically represents 20% of total RAS in most cell lines. Data
taken from [43].
sequence [11].Overexpression of oncogenicallymutatedRAS
is known to induce senescence rather than proliferation
[12]. The authors speculated that the rare codon usage in
KRAS leads to low endogenous protein levels, meaning
that oncogenically activated KRAS would not be expressed
highly enough to induce the senescent phenotype. Absolute
quantification of RAS isoform protein abundance in normal
tissues has not been performed to date; however, comparative
analysis of RAS isoform protein levels in a panel of cancer
cell lines revealed that KRAS is typically the most abundant
isoform (Figure 2). Therefore whether the preponderance of
KRAS mutations in cancer is linked to relative abundance of
the isoforms remains an open question.
Finally, whereas RAS isoforms are identical at the amino
acid level in the region containing the mutated codons,
Figure 3 RAS isoform codon mutation bias in human cancers
(A) A survey of RAS mutations across all cancers reveals that KRAS
favours mutation at codon 12, whereas NRAS is typically mutated at
codon 61. (B) Analysis of individual tumour types with 20 mutations
of each isoform reveals similar codon biases. Data from Sanger COSMIC
(Catalog of Somatic Mutations in Cancer) version 52 dataset and collated
in [8].
their DNA sequences differ. Differences in adduct repair
rates between the isoforms may explain the abundance of
KRASmutations. Evidence for this comes from Tang and co-
workers who found that tobacco smoke mutagen adducts
at codon 12 of KRAS were repaired less efficiently than
those in HRAS or NRAS [13,14]. The mechanistic basis
for this may be due to local sequence-dependent differences
in DNA curvature that are recognized by the DNA repair
enzymes.
Mutations at codons 12, 13 and 61 account for over 99%of
all RAS mutants detected in cancer [8]. An intriguing feature
is the preference of each isoform for mutation at different
codons, with NRAS being typically mutated at codon 61
whereas 80%ofKRASmutations are at codon12 (Figure 3A).
Single base substitutions can result in conversion into six
other amino acids at codons 12, 13 and 61. Despite this,
over 60% of the total mutations observed for each isoform
are accounted for by only three of the 18 possible codon
variants [8]. RAS isoform-specific bias is also evident inwhich
mutations are typically seen at each codon. For example,
G12V mutations are ten times more abundant than G12D
mutations in HRAS cancer samples, whereas for KRAS and
NRAS G12D mutations predominate [8].
c© 2014 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
744 Biochemical Society Transactions (2014) Volume 42, part 4
Some of the mutational heterogeneity will be due to
tissue-specific exposure to different cocktails of mutagens.
For example, the G12C mutation observed in KRAS in
lung cancers is associated with exposure to tobacco smoke
mutagens [15]. However, this does not explain why there is
still codon mutation bias between isoforms within the same
cancer. Thyroid and skin cancers are the only two cancer
types where substantial numbers of mutations of all three
isoforms are observed. In both cases, the bias towards codon
61 mutations forNRAS and codon 12 mutations for KRAS is
clear (Figure 3B).
Given that mutations at codons 12, 13 and 61 are all
activating in all of the isoforms, does it matter which
codon is mutated or which substitution has occurred? Cell
transformation is used as a read-out for oncogenic RAS
function, and early comparative studies revealed a spectrum
of transforming capabilities among HRAS codon 12 and
codon 61 mutants [16,17]. In vitro experiments revealed
that cells expressing KRAS codon 12 mutations were more
resistant to apoptosis than codon 13 mutant cells [18]. More
recently, direct clinical support for codon-specific signalling
was observed in colorectal cancer. Patients with KRAS
codon 13 mutations have a worse prognosis than those with
KRAS mutated at codon 12 [19,20]. A first-line therapy
for patients with advanced colorectal cancer is the anti-
EGFR (epidermal growth factor receptor) drug cetuximab;
however, this is was thought to be ineffective for patients
with KRAS mutations. For this reason, routine screening of
colorectal cancer patients for KRASmutations is now carried
out. However, meta-analysis of cetuximab resistance data
found that patients with KRAS G13D mutations showed
significant improvements in survival [20]. Finally, different
codon mutations are differentially sensitive to allosteric
regulation of RAS that normally stimulates intrinsic GTPase
activity. Codon 61 but not codon 12 is critical for stabilizing
this allosteric switch required for promoting GTP hydrolysis
[21]. However, codon 61 mutants are switched into the anti-
catalytic conformation when bound to RAF, this means
that these mutants are particularly potent activators of
the RAF/MAPK pathway compared with the other codon
mutants [22].
Therefore the functional consequences of different RAS
mutations are not necessarily equivalent. This represents
an important emerging concept that is likely to inform
the design of experiments, screens and trials in the coming
years.
Isoform-speciﬁc RAS signalling
Differential RAS isoform mutation frequencies and coupling
to individual cancers suggests isoform-specific function.
Other in vivo support is provided by studies of mouse
developmentwhereKRASknockout is embryonic lethal [23].
In contrast, double knockout of HRAS andNRAS produced
viable offspring with no obvious negative phenotypic
consequences [24]. Comparative in vitro studies involving
ectopic overexpression of each of the isoforms revealed
preferential coupling of KRAS with the RAS/MAPK
pathway and HRAS and NRAS with PI3K/Akt activation
[25,26].
The mechanistic basis for isoform-specific signalling is
thought to lie, at least in part, in the different trafficking
and overlapping, but distinct, subcellular localizations of
each isoform [27]. This is governed by the 25/26-amino-acid
C-terminal hypervariable region that is post-translationally
modified to allow membrane binding [28]. All RAS isoforms
contain a C-terminal CAAX motif that is farnesylated
before proteolysis to remove the -AAX residues and
carboxymethylation [29]. The weak membrane affinity is
supplemented by either palmitoylation in the case of HRAS,
NRAS and the KRAS4A splice variant or a stretch of basic
lysine residues in KRAS4B [30]. Palmitoylation specifies
trafficking via the Golgi to the plasma membrane and
differential localization within cell surface nanoclusters [31–
33]. This modification is reversible, and depalmitoylation
allows a dynamic flux between the cell surface and the Golgi
complex [34,35]. Electrostatic interactions direct reversible
KRAS4B localization with the plasma membrane [31,32].
In contrast with the palmitoylated RAS isoforms, almost
no endomembranous localization is observed for KRAS4B
[4]. Although the plasma membrane is the main site of
action of RAS, subcellular organelles have been shown to be
competent to support RAS function [36–38]. Differences in
localization between the RAS isoforms are thought to bring
them into contact with different concentrations of regulators
and effectors to generate overlapping, but distinctive, outputs
[27,39].
A second mechanism for generating isoform-specific
signalling is via differences in the presentation of the effector-
binding domain.UponGTPbinding, theG-domain (residues
1–166) of RAS isoforms change their orientation with respect
to the membrane [40]. The extent of this reorientation varies
between the isoforms and binding of the key RAS effectors
PI3K and RAF is sensitive to these changes. RAF binding
is favoured by the KRAS orientation, whereas PI3K binding
favours that adopted by HRAS [41].
Finally, relative expression differences of the isoforms will
influence competition for regulator and effector binding and
therefore signalling network responses. An example of this
can be seen in studies of mouse development. WhereasKRAS
knockout resulted in embryonic lethality [23], a subsequent
study inserted HRAS into the endogenous KRAS locus,
resulting in normal embryonic development, but induced
dilated cardiomyopathy during adulthood [42]. This suggests
that HRAS can functionally replace KRAS during early
development, but only when expressed under the control of
KRAS-regulatory promoter regions.
This illustrates the importance of studying isoform-
specific function in an endogenous context, since a subset
of isoform-specific differences may result from the disparity
in their expression. Future work is likely to rely less on
ectopic overexpression andmore on isogenic cells harbouring
endogenous wild-type and mutant RAS alleles, panels of
cancer cell lines and mouse models.
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Conclusions
RAS proteins exhibit a spectrum of isoform-, codon-,
point-mutation- and context-specific network responses.
These remain poorly understood, which precludes simple
prediction of the likely consequences of any given mutation.
Wherever possible, it is important to study RAS function in
an endogenous context to avoid the perturbing influence of
overexpression on the signalling networks. With the recent
emergence of new cellular tools, xenopatient and genetically
engineered mouse models and more sophisticated systems
biology approaches to studyingRAS function, there are likely
to be significant improvements in our understanding of RAS
biology in the near future.
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